Â鶹ӳ»­

CAR T Cell Clinical Trials

Lymphoma CAR T Cell Clinical Trials

2024-0431 A randomized, open-label study evaluating the efficacy and safety of cemacabtagene ansegedleucel in participants with minimal residual disease after response to first line therapy for large B cell lymphoma (ALPHA3)

2022-0938 A  Phase I study of JV-213 autologous CD79b-targeting chimeric antigen receptor T cell therapy in adults with relapsed or refractory B-cell lymphomas

2020-1136 A Phase I open-label, multicenter study evaluating the safety and efficacy of KITE-363, an autologous anti-CD19/CD20 CAR T cell therapy, in subjects with relapsed and/or refractory B cell lymphoma

2023-0673 A Phase II study of axicabtagene ciloleucel and glofitamab as second-line therapy for relapsed or refractory patients with large B Cell lymphoma

Myeloma CAR-T Clinical Trials

2024-1162 A Phase Ib/II study of AZD0120, dual-targeting autologous chimeric antigen receptor T cell (CAR T) therapy directed against CD19 and B-cell maturation antigen (BCMA) in participants with relapsed/refractory multiple myeloma

2023-0502 A Phase I, multicenter, open-label study to evaluate the safety and preliminary efficacy of arlocabtagene autoleucel (BMS-986393) in novel combinations in participants with relapsed and/or refractory multiple myeloma and determine the recommended dose for each add-on investigational component

2023-1048 A Phase II, open-label, multicenter study of BMS-986393, a GPRC5D-directed CAR T cell therapy in adult participants with relapsed or refractory multiple myeloma (QUINTESSENTIAL)

2024-1148 A Phase III, randomized, open-label study to compare the efficacy and safety of anitocabtagene autoleucel versus standard of care therapy in participants with relapsed/refractory multiple myeloma

2025-1334 A modular, Phase I, open-label, multicenter study to evaluate the safety, tolerability, cellular kinetics, immunogenicity, pharmacodynamics, and preliminary efficacy of AZD0120, a dual-targeting autologous chimeric antigen receptor T cell (CAR-T) therapy directed against BCMA and CD-19 in participants with multiple myeloma

Lymphoma Clinical Trials

Indolent Lymphoma (Follicular, Marginal Zone, Small Lymphocytic Leukemia)

2024-0385 Randomized Phase III study of mosunetuzumab vs. rituximab for low tumor burden follicular lymphoma

2023-0063 Phase II trial of obinutuzumab and CC-99282 for patients with previously untreated high tumor burden follicular lymphoma

2025-1358 A modular Phase II, single-arm, multicenter, open-label study to evaluate the efficacy and safety of surovatamig (AZD0486) in participants with relapsed or refractory B cell non-Hodgkin lymphoma (SOUNDTRACK-B)

2022-0463 An adaptive Phase III, randomized, open-label, multicenter study to compare the efficacy and safety of axicabtagene ciloleucel versus standard of care therapy as first-line therapy in subjects with high-risk large B cell lymphoma

 A Phase lb, open-label, multicenter study evaluating the safety, pharmacokinetics, and efficacy of mosunetuzumab or glofitamab in combination with CC-220 and CC-99282 in patients with B cell non-Hodgkin lymphoma

2022-0551 A Phase I/II, open-label study of valemetostat in combination with rituximab and lenalidomide in relapsed or refractory follicular lymphoma

2022-0459 A Phase II trial of mosunetuzumab, polatuzumab, tafasitamab, and lenalidomide in patients with relapsed B cell NHL

2025-0865 A multi-center single arm Phase II study to evaluate the safety and efficacy of genetically engineered autologous cells expressing anti-CD20 and anti-CD19 specific chimeric antigen receptor in subjects with relapsed and/or refractory diffuse large B cell lymphoma

2025-1078 Pivotal study to validate the usability, safety and diagnostic performance of a novel system to non-invasively detect severe neutropenia

2024-0114 A Phase III, multicenter, randomized, open-label trial to evaluate the safety and efficacy of epcoritamab + rituximab and lenalidomide (R 2) compared to chemoimmunotherapy in previously untreated follicular lymphoma (EPCORE FL-2)

Aggressive Lymphoma (Large B cell Lymphoma, Diffuse Large B cell Lymphoma, Burkitt's Lymphoma)

2020-1169 A Phase I, dose escalation, safety and tolerability study of NX-2127, a Bruton's tyrosine kinase (BTK) degrader in adults with relapsed/refractory B cell malignancies

2021-1033 An open-label, multi-center, non-randomized Phase I dose escalation study to investigate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ONO-4685 given as monotherapy in patients with relapsed or refractory T cell lymphoma

2022-0602 An open-label, Phase I study to evaluate the safety, pharmacokinetics and preliminary anti-tumor activity of RO7227166 (a CD19 targeted 4-1BB ligand) in combination with obinutuzumab and in combination with glofitmab following a pre-treatment dose of obinutuzumab administered in participants with relapsed/refractory B cell non-Hodgkin's lymphoma

2022-0147 A Phase II study of loncastuximab tesirine as consolidation strategy in patients with large B cell lymphoma who achieve partial remission after CAR T cell therapy

2021-1088 A multicenter, open-label feasibility and randomized Phase II study of daratumumab with dose-adjusted EPOCH in newly diagnosed plasmablastic lymphoma with or without HIV

2023-0202 A Phase I multicenter study evaluating the safety and efficacy of ACE1831, an allogeneic CD20-conjugated gamma delta T cell therapy, In adult subjects with relapsed/refractory CD20-expressing B cell malignancies

 A Phase II trial of mosunetuzumab and zanubrutinib for patients with relapsed/refractory marginal zone lymphoma

2023-0031 Phase II trial of epcoritamab in combination with rituximab-mini CVP for older unfit/frail patients or anthracycline-ineligible adult patients with newly diagnosed diffuse large B cell lymphoma

2021-1108 Phase II study of pirtobrutinib with venetoclax in relapsed-refractory MCL (mantle cell lymphoma) patients

2025-0872 An open-label, multicenter, Phase I trial to evaluate the safety, pharmacokinetics, and anti-tumor activity of TLN-121 as a single agent and in combination with other anti-lymphoma agents, in patients with relapsed or refractory non-Hodgkin lymphomas

2023-0942 A modular Phase I/II, open-label, multicenter study to evaluate the safety, tolerability and efficacy of AZD3470, a PRMT5 inhibitor, as Monotherapy and in combination with Anti-cancer Agents in participants with relapsed/refractory Hematologic Malignancies

2023-0864 A pilot study of emapalumab for the treatment of CAR T cell therapy-associated prolonged cytopenia

2024-0115 A Phase III, randomized, open-label study comparing the efficacy and safety of the combination of Beleodaq-CHOP or Folotyn-COP to the CHOP regimen alone in newly diagnosed patients with peripheral T cell lymphoma

2024-0453 An open-label, dose escalation and dose expansion trial evaluating the safety, pharmacokinetics, pharmacodynamics, and clinical activity of orally administered CA-4948 in patients with relapsed or refractory primary central nervous system lymphoma

2024-0430 A Phase I first in human study of ARV-393 in adult participants with advanced non-Hodgkin's lymphoma

2024-1146 A Phase III, multicenter, randomized, double-blind, placebo-controlled study comparing the efficacy and safety of golcadomide plus R-CHOP chemotherapy vs placebo plus R-CHOP chemotherapy in participants with previously untreated high-risk large B cell lymphoma

2024-1534 A Phase II, open-label, multicenter study of MB-105 in patients with CD5 positive (CD5+) relapsed/refractory T cell lymphoma (r/r TCL)

2024-1549 A modular Phase I/II open-label dose escalation and dose expansion study to evaluate the safety, pharmacokinetics, pharmacodynamics, and efficacy of AZD5492, a T cell-engaging antibody targeting CD20 in subjects with relapsed or refractory B cell malignancies (TITANium) 

2025-0344 A Phase II/III, open-label, single-arm, multicenter, historical control study to evaluate ELA026 in participants with secondary hemophagocytic lymphohistiocytosis (sHLH)

2023-0176 A pilot study for pupillary assessment to predict CAR-T related neurotoxicity

2020-0034 A Phase II Study of acalabrutinib, lenalidomide and rituximab (aR2) in patients with previously untreated high tumor burden follicular lymphoma

Mantle Cell Lymphoma

2022-0722 A single-arm, open-label, multicenter Phase II study to evaluate the efficacy, safety, and pharmacokinetics of Bcl-2 inhibitor BGB-11417 in patients with relapsed or refractory mantle cell lymphoma

2023-0695 Tafasitamab, lenalidomide and venetoclax combination therapy for relapsed or refractory Mantle Cell Lymphoma (V-MIND)

2023-0413 Phase II study of pirtobrutinib, rituximab (PR) in previously untreated low and intermediate risk MCL (mantle cell lymphoma) patients

2024-0220 GATE1: A multicenter Phase II study of pirtobrutinib, rituximab and venetoclax combination therapy for patients with previously untreated mantle cell lymphoma

2024-1726 Phase I trial of BTM-3566 in relapsed/refractory mature B cell lymphomas

2025-0045 A Phase III randomized double-blind multicenter study of sonrotoclax plus zanubrutinib versus placebo plus zanubrutinib in patients with relapsed/refractory mantle cell lymphoma

Hodgkin Lymphoma

2021-0091 A multicenter, Phase I, open-label, dose-escalation and expansion study of TNB-486, a bispecific antibody targeting CD19 in subjects with relapsed or refractory B cell non-Hodgkin lymphoma

T Cell Lymphoma

Previously Treated

2023-0962 A Phase III, randomized, open-label study to investigate the efficacy and safety of ITK inhibitor soquelitinib versus physician's choice standard of care treatment (selected single agent) in participants with relapsed/refractory peripheral T cell lymphoma not otherwise specified, follicular helper T cell lymphomas, or systemic anaplastic large-cell lymphoma

Multiple Myeloma Clinical Trials

Newly Diagnosed

2024-0160 A Phase I/II study of linvoseltamab in patients with relapsed or refractory systemic light chain amyloidosis

 SWOG S2209: A Phase III randomized trial for newly diagnosed multiple myeloma (NDMM) patients considered frail or in a subset of "intermediate fit" comparing upfront three-drug induction regimens followed by double- or single-agent maintenance

2021-0191 (DETER-SMM) EAA173: Daratumumab to enhance therapeutic effectiveness of revlimid in smoldering myeloma (DETER-SMM)

2020-0431 A Phase I with extension cohort, single arm, single center, open label trial of belantamab mafodotin for the treatment of high-risk smoldering multiple myeloma

2023-0363 Phase I/II study of linvoseltamab (anti-BCMA X Anti-CD3 bispecific antibody) in previously untreated patients with symptomatic multiple myeloma (Linker-MM4 Study)

2021-0185 A Phase I/IIa, first-in-human study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of HDP-101 in patients with plasma cell disorders including multiple myeloma

2023-0420 Phase I/II study of IDP 023 as a single agent and in combination with antibody therapies in patients with advanced hematologic cancers

2024-1019 SWOG: Study s2213 a Phase III, randomized study of daratumumab, cyclophosphamide, bortezomib and dexamethasone (DaraVCD) induction followed by autologous stem cell transplant or Dara-VCD consolidation and daratumumab maintenance in patients with newly diagnosed AL amyloidosis

2021-0191 EAA173: Daratumumab to enhance therapeutic effectiveness of revlimid in smoldering myeloma (DETER-SMM)

Relapsed or Refractory

2023-0719 A Phase III, two-stage, randomized, multicenter, open-label study comparing mezigdomide (CC-92480), bortezomib and dexamethasone (MeziVd) versus pomalidomide, bortezomib and dexamethasone (PVD) in subjects with relapsed or refractory multiple myeloma (RRMM): successor-1

2023-0527 Phase I/II open label study of belumosudil mesylate alone, and in combination with dexamethasone, in patients with relapsed/refractory multiple myeloma

2025-0836 A Phase Ib/IIa, multicenter, open-label study to determine the recommended dose and schedule, and evaluate the safety and preliminary efficacy of Mezigdomide in combination with Elranatamab in participants with relapsed and/or refractory multiple myeloma

2024-0003 Phase I, First-in-Human, Dose Escalation Study of JNJ-79635322, a Trispecific Antibody, in Participants with Relapsed or Refractory Multiple Myeloma or Previously Treated AL Amyloidosis

Other Clinical Trials

 A Phase I/II study of linvoseltamab in patients with relapsed or refractory systemic light chain amyloidosis

2023-0942 Study of AZD3470 in participants with relapsed/refractory hematologic malignancies

2023-0864 A pilot study of Emapalumab for the treatment of CAR T cell therapy-associated prolonged cytopenia

2023-0581 A randomized trial of fecal microbiota transplantation for remedying antibiotics-induced microbiota dysbiosis in lymphoma patients receiving axicabtagene ciloleucel therapy

 A multicenter, open-label feasibility study of daratumumab with dose-adjusted EPOCH in newly diagnosed plasmablastic lymphoma with or without HIV

2022-0396 Feasibility of combined genomics/transcriptomics for patients with lymphoma

2021-0440 A collection of blood and tissue samples from patients with amyloidosis and/or monoclonal gammopathies (including lymphoplasmacytic lymphoma) and normal donors

 An open-label Phase II study to investigate the efficacy, safety, and pharmacokinetics of tirabrutinib in patients with primary central nervous system lymphoma (PCNSL)

2022-0918 Expanded access study for the treatment of patients with commercially out-of-specification axicabtagene ciloleucel

2023-0420 Phase I/II study of IDP 023 as a single agent and in combination with antibody therapies in patients with advanced hematologic cancers